A decision by the German health technology assessment agency IQWiG that new analysis provided by Bayer of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) result in the product's disadvantages outweighing its benefits "is essentially incomprehensible to Bayer," the German pharma told Scrip.
Stivarga has been approved in Europe since 2013 for adults with mCRC for whom previous treatments are no longer effective...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?